Abstracts Archive - Page 1237 of 1683 - ATC Abstracts

2016 American Transplant Congress
Antibody Titers as Predictors of Kidney Graft Outcomes.
A. Gilbert,¹ M. Zaheer,¹ O. Timofeeva,² S. Rosen-Bronson,² M. Awwad,² D. Li,² M. Grafals,¹ B. Javaid,¹ P. Abrams,¹ J. Verbesey,¹ M. Cooper.¹
¹Surgery, MedStar Georgetown Transplant Institute, Washington, DC; ²Pathology, MedStar Georgetown Transplant Institute, Washington, DC.
PURPOSE: Development of de novo donor specific antibody (dnDSA) following kidney transplantation is not uncommon. As laboratory techniques advance, rates of dnDSA have increased. However,…
2016 American Transplant Congress
Deceased Donor Kidney Transplantation in the Setting of Positive Donor-Specific Antibodies.
B. Orandi,¹ J. Montgomery,² E. Kraus,¹ D. Segev,¹ R. Montgomery,¹ N. Alachkar.¹
¹Johns Hopkins University, Baltimore; ²University of Michigan, Ann Arbor.
Recent changes to the kidney allocation system favor highly sensitized transplant candidates, resulting in these patients receiving more offers for deceased donor (DD) kidneys. Despite…
2016 American Transplant Congress
Antibody-Mediated Rejection Can Be Assessed by Histology When DSA Is Unknown or Negative.
J. Reeve,¹ P. Halloran.²
¹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ²Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Diagnosis of antibody-mediated rejection (ABMR) in kidney transplants currently requires the presence of donor-specific antibody (DSA) and histologic lesions above somewhat arbitrary cutoffs. DSA is…
2016 American Transplant Congress
Baseline Donor Specific Antibody (DSA) More Predictive of Chronic Antibody Mediated Rejection (CAMR) Than the Change in DSA Over Time.
D. Mitema,¹ W. Cheungpasitporn,¹ M. Stegall,¹ F. Cosio,¹ M. Gandhi,² C. Schinstock.¹
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; ²Division of Transfusion Medicine, Mayo Clinic, Rochester, MN.
Introduction: Although therapies are available to at least temporarily reduce DSA, the change in DSA naturally post-transplant remains unknown. We aim to study the serial…
2016 American Transplant Congress
Preformed Antibodies Against AT₁R and EDNRA Correlate with Rejection Post-Transplant.
A. Gareau,¹ C. Wiebe,^1,2 D. Pochinco,² I. Gibson,³ D. Rush,¹ P. Nickerson.^1,2,4
¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; ²Diagnostic Services of Manitoba, Winnipeg, MB, Canada; ³Pathology, University of Manitoba, Winnipeg, MB, Canada; ⁴Immunology, University of Manitoba, Winnipeg, MB, Canada.
Studies have investigated the potential pathogenic effects of non-HLA antibodies (Ab), with a few reporting that Ab against the angiotensin II type 1 receptor (AT1R)…
2016 American Transplant Congress
The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.
S. Ge, M. Chu, J. Choi, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplantation in HLA-sensitized patients. ADCC is one of the primary mechanisms for ABMR. IdeS cleaves…
2016 American Transplant Congress
Optimized Flow Cytometry Crossmatch with Increased Sensitivity and Specificity.
K. Barrios,¹ J. Lunz,¹ B. Labuda,¹ D. Magas,¹ D. Freedom,¹ K. Szewczyk,¹ M. Jendrisak,¹ A. Jaramillo.^1,2
¹Gift of Hope Organ & Tissue Donor Network, Itasca, IL; ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
The flow cytometry crossmatch (FCXM) is the standard method to prevent hyperacute rejection after transplantation. Surprisingly, few technical improvements have been introduced to the FCXM…
2016 American Transplant Congress
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.
G. Einecke,¹ J. Bräsen,² A. Schwarz,¹ H. Haller,¹ F. Njau.¹
¹Nephrology, Medical School of Hannover, Hannover, Germany; ²Pathology, Medical School of Hannover, Hannover, Germany.
Antibody-mediated rejection (AMR) is a major cause of late renal allograft failure. The benefit of treatment of chronic ABMR is unknown. Currently there is no…
2016 American Transplant Congress
Early Onset Acute Antibody Mediated Rejection (ABMR) Is More Common in Female Than in Male Recipients of a Living Unrelated Donor (LURD) Renal Transplant and Is Associated with the Presence of Preformed Donor Specific Antibodies (DSA).
D. Soonawala,¹ K. Groeneweg,¹ F. van der Toorn,¹ S. Heidt,² D. Roelen,² F. Claas,² J. de Fijter.¹
¹Nephrology, LUMC, Leiden, Netherlands; ²IHB, LUMC, Leiden, Netherlands.
Introduction: Women who receive a renal graft from their male spouse have a higher risk of early onset acute ABMR. The aim of this study…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…